06:50 EST Cidara Therapeutics (CDTX) jumps 104% to $216.26 after Merck (MRK) buyout offer
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDTX:
- Merck close to deal to acquire Cidara Therapeutics, FT reports
- Cidara Therapeutics’ Earnings Call Highlights CD388 Progress
- Cidara Therapeutics price target raised to $145 from $137 at RBC Capital
- Positive Outlook on Cidara Therapeutics: Progress in CD388 Flu Program and Strategic Trial Advancements
- Cidara Therapeutics Advances CD388 with Phase 3 Expansion